Mon has been reported to inhibit RANKL-induced osteoclastogenesis [40], and it may exhibit a potential therapeutic effect on bone erosion in RA by inhibiting both LPS- and RANKL-related signaling pathways to reduce the pathological over-activation of OCs. This evidence concerns the gene TNFSF11 and rheumatoid arthritis.